Products

Human HLA-A*11:01&B2M&KRAS G12D Monomer

Overview Specification

Product Name	Human HLA-A*11:01&B2M&KRAS G12D Monomer
Cat. No.	MHCRP-0587
Category	Proteins & Peptides
Product Description	Recombinant Human HLA-A11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A11:01),Ile21-Met119 (B2M) and VVVGADGVGK peptide.
Size	100/500 μg
Format	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Storage	Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping Temp	Shipped with dry ice.
Lead Time	Product delivery time depends on the supplier.
Species	Human
Expression Host	HEK293
Accession No	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK
Tag	C-His-Avi
Tag Position	C-terminus
Molecular Type	Monomer
Molecular Weight (MV)	The protein has a predicted MW of 50.3 kDa. Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.
Gene Synonyms	MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Endotoxin Residue	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC.
Amino Acid Range	Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M), and VVVGADGVGK peptide
Activity	Immobilized HLA-A11:01&B2M&KRAS G12D (VVVGADGVGK) TCR at 5 μg/mL (100 μL/well) on the plate. Dose response curve for human HLA-A11:01&B2M&KRAS G12D (VVVGADGVGK) monomer, His tag with the EC50 of 0.39 μg/mL determined by ELISA (QC Test). The affinity constant of 14.91 nM as determined in SPR assay.
Product Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
Allele	HLA-A*11:01
Biotinylated	No

For research or industrial raw materials, not for personal medical use!